Global Paclitaxel Injection Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Paclitaxel Injection is a kind of anti-cancer injection taking paclitaxel API as raw material. It is mainly used in breast cancer, ovarian cancer and other cancers.
Paclitaxel injection comes as a liquid to be given intravenously (into a vein) by a doctor or nurse in a hospital or clinic. It is usually given once every 3 weeks. When paclitaxel injection manufactured with polyoxyethylated castor oil is used to treat Kaposi's sarcoma, it may be given once every 2 or 3 weeks.
According to our (Global Info Research) latest study, the global Paclitaxel Injection market size was valued at USD 3482 million in 2022 and is forecast to a readjusted size of USD 7058.9 million by 2029 with a CAGR of 10.6% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Paclitaxel Injection key players include Bristol-Myers Squibb, Celgene Corporation, Hospira, Biological E., Luye Pharma, etc. Global top five players hold a share about 80%.
Europe is the largest market, with a share about 25%, followed by North America and China, having a total share about 40 percent.
In terms of product, 5ml,30mg is the largest segment, with a share about 75%. And in terms of application, the largest application is Ovarian Cancer, followed by Breast Cancer, Cervical Cancer, Pancreatic Cancer.
This report is a detailed and comprehensive analysis for global Paclitaxel Injection market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Paclitaxel Injection market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Paclitaxel Injection market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Paclitaxel Injection market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Paclitaxel Injection market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Paclitaxel Injection
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Paclitaxel Injection market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bristol-Myers Squibb, Celgene Corporation, Hospira, Biological E. and Taj Accura, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Paclitaxel Injection market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
    5ml,30mg
    10ml,60mg
    16.7ml,100mg
    25ml,150mg
    50ml,300mg
Market segment by Application
    Ovarian Cancer
    Breast Cancer
    Cervical Cancer
    Pancreatic Cancer
    Other
Major players covered
    Bristol-Myers Squibb
    Celgene Corporation
    Hospira
    Biological E.
    Taj Accura
    Khandelwal Laboratories
    Luye Pharma
    Beijing Youcare
    Beijing Union
    Haiyao
    Chuntch
Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Paclitaxel Injection product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Paclitaxel Injection, with price, sales, revenue and global market share of Paclitaxel Injection from 2018 to 2023.
Chapter 3, the Paclitaxel Injection competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Paclitaxel Injection breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Paclitaxel Injection market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Paclitaxel Injection.
Chapter 14 and 15, to describe Paclitaxel Injection sales channel, distributors, customers, research findings and conclusion.